



- (51) **International Patent Classification:**
G06F 19/00 (2011.01)
- (21) **International Application Number:**
PCT/US2013/056020
- (22) **International Filing Date:**
21 August 2013 (21.08.2013)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
61/691,706 21 August 2012 (21.08.2012) US
- (71) **Applicant:** **CRITICAL CARE DIAGNOSTICS, INC.**
[US/US]; 3030 Bunker Hill Street, Suite 117A, San Diego,
CA 92109 (US).
- (72) **Inventors:** **SNIDER, James, V.**; 1167 Hornblend Street,
San Diego, CA 92109 (US). **GERWIEN, Robert, W.**; 56
Francis Avenue, Newington, CT 06111 (US). **JACOB-
SON, Sven**; 121 Reade Street, Apt 9B, New York, NY
10013 (US).
- (74) **Agents:** **REITER, Tiffany** et al.; Fish & Richardson P.C.,
P.O. Box 1022, Minneapolis, MN 55440-1022 (US).
- (81) **Designated States** (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,

DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM,
ZW.

- (84) **Designated States** (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

[Continued on next page]

- (54) **Title:** MULTIMARKER RISK STRATIFICATION

Fig. 27 Top 10 Models
1 Year Outcomes (Size =1-5)

	Standardized Hazard Ratios										Model Fit			Discrimination							
	Age_Yr	ST2	Troponin	NTproBNP	NYHA	SBP120	CAD	BMI	BMIge25	lnTpro	lnCreat	lnHGB	Diabetes	logLik	AIC	BIC	AUC	bsAUC	LCI	UCI	
Model No	Age_Yr	ST2	ST2ge50	ST2-3g	lnTroponinTROPONINge16	NYHA	SBP120	CAD	BMI	BMIge25	lnTpro	lnCreat	lnHGB	Diabetes							
13488	5	1.66	1.48		1.53	1.29	0.85								-532.0	1074.1	1098.0	0.802	0.795	0.734	0.855
16905	5	1.74	1.45		1.45	1.29	1.18								-532.0	1074.1	1098.0	0.804	0.794	0.738	0.850
11944	5	1.76	1.50		1.51										-534.0	1077.9	1101.9	0.801	0.792	0.731	0.854
16189	5	1.69	1.47		1.50	1.30			0.81		0.99				-533.2	1076.4	1100.3	0.800	0.792	0.728	0.856
16825	5	1.61	1.42		1.46	1.36					1.16				-533.8	1077.7	1101.6	0.795	0.792	0.725	0.859
13506	5	1.64	1.54		1.64	1.32	0.87								-533.3	1076.6	1100.6	0.799	0.792	0.713	0.871
3524	4	1.65		1.57	1.57	1.34									-534.0	1076.0	1095.2	0.795	0.790	0.734	0.846
16987	5	1.68	1.43		1.53	1.35	1.19								-533.1	1076.2	1100.1	0.798	0.789	0.732	0.847
11372	5	1.62	1.45		1.43	1.32			0.78						-531.3	1072.6	1096.5	0.804	0.789	0.715	0.863
16650	5	1.84	1.48		1.46	1.22					0.78				-532.1	1074.2	1098.2	0.797	0.789	0.723	0.855

Markers Not Selected:

Ln (eGFR)

SBP

DBP

LVEF

NT-proBNP>=1700

GFR<50

ST2 >= 35

Sex

Hypertension

- (57) **Abstract:** Measurement of circulating ST2 and natriuretic peptide (e.g., NT-proBNP) concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, transplantation, and heart failure.



-
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*